When you start a medication like Dupixent (dupilumab), you expect relief from eczema or asthma, not the devastation of a cancer diagnosis. Yet ...

Q. In a recent article about the challenges of treating eczema (atopic dermatitis), you described a number of over-the-counter treatments as well as modern prescription medicines. In particular, you ...

This is an active lawsuit, and none of the allegations against the defendant(s) have been proven. The contents of this page reflect the allegations in the lawsuits. Cutaneous T-cell lymphoma (CTCL) is ...

Dupixent (dupilumab) has been a breakthrough treatment for people with severe eczema, asthma, and other inflammatory conditions. For many, it has provided relief when other therapies failed. However, ...

(HealthDay News) — Dupixent (dupilumab) has been approved by the US Food and Drug Administration to treat moderate-to-severe eczema that isn’t well controlled by topical medication. The active ...

The European Commission (EC) approved Sanofi (NASDAQ:SNY) and Regeneron Pharmaceuticals' (NASDAQ:REGN) Dupixent to treat severe atopic dermatitis (eczema) in children aged six months to five years old ...

Sanofi SNY and partner Regeneron REGN announced that the European Commission has approved their blockbuster medicine, Dupixent, for children six months to five years of age with severe atopic ...

Danielle Jonas spoke to Insider about her experience with moderate eczema. Jonas said she was "uncomfortable with myself," before using Dupixent as a treatment for her condition. Because of her eczema ...

Regeneron Pharmaceuticals beat Wall Street estimates for third-quarter results on Tuesday, helped by strong demand for its eczema treatment, Dupixent, and cancer treatment Libtayo, sending shares up ...

Regeneron stock increased by 19% over the past month, driven by strong third-quarter earnings. But is Gilead the better pick?